In this video, Dr. Tufia Haddad answers questions about treatment options, recent drug approvals, clinical trials, symptoms and SERM - Selective Estrogen Receptor Modulators AstraZeneca's oral SERD hits goal in phase 3 breast cancer trial
EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective
With Aditya Bardia, MD, MPH. SERENA-1 Parts K/L: camizestrant and ribociclib in ER+/HER2- breast cancer SERDs in premenopausal breast cancer: improving outcomes & treatment options
Download Outcomes4Me: Watch the full interview here: Antonio Llombart-Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II
Drugs: Tamoxifen and Raloxifene Mechanism of action: Competitive inhibitor of estrogen binding Mixed agonist/antagonist action Research Month: Antibody Drug Conjugates in Breast Cancer In a conversation with CancerNetwork®, Erica Mayer, MD, MPH, director of breast cancer research at Dana-Farber Cancer
How Can I Understand Different Hormone Therapy Drugs For Breast Cancer? Are you curious about how hormone therapy drugs What Are The Next-generation Chemoprevention Drugs For Breast Cancer? In today's headlines – 21 October: - Has Roche taken a lead in the oral SERD category of breast cancer therapies with data
How Are New Drugs Treating Metastatic Breast Cancer? - Breast Cancer Support Channel Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Brea Definition of SERD - NCI Dictionary of Cancer Terms - NCI
Phase I Study of Investigational Drug Elacestrant (RAD1901) One of the drugs is able to reach tumors that have spread to the brain.
ER degrader safe, with signs of antitumour activity against ER-positive breast cancer New drugs show rare promise against aggressive breast cancer Medical updates in MBC: What you need to know
ESMO25 Breast Cancer Highlights: evERA and SERENA6 | Dana-Farber Cancer Institute This session took place at 3:30 p.m. Wednesday, Dec. 11, 2025. It was an Educational Session. YOUTUBE CHAPTERS 0:00 SERDs are a drug class that targets estrogen receptor alpha (ERα) for proteasome-dependent degradation. SERDs can induce receptor degradation by
Selective Estrogen Receptor Modulator (SERM) New Oral Selective Estrogen Receptor Degraders Redefine
8 Oral SERDs for Breast Cancer in Development - GoodRx Patient eligibility in the AMEERA-6 trial of amcenestrant In this clip from Breast Cancer Breakthroughs Episode 11, medical oncologist Dr. Priya Rastogi discusses how she envisions new
OP-1250: a small molecule oral complete estrogen receptor antagonist (CERAN) Selective estrogen receptor modulators
FDA approves elacestrant for ER-positive, HER2-negative, ESR1 Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, discusses findings from the phase III AMEERA-6 trial
SABCS 2024: Unlocking new targets with molecular degraders Nikhil Wagle, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of resistance to endocrine therapies and The trial hit on progression-free survival, its primary endpoint, but is yet to show patients live longer on the drug candidate.
Antonio Llombart-Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, highlights the potential benefits of Trending in Women's Health: IBD in pregnancy, SERD win and more
AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer I have been randomized into the new drug arm of the CAMBRIA-2 study. That means I will get the new drug: Camizestrant, which Sean Bohen, MD, PhD, Olema Oncology, San Francisco, CA, provides an overview of OP-1250, a complete estrogen receptor
Erika Hamilton, MD, from Sarah Cannon Research Institute in Nashville, TN, discusses the landscape of oral Selective Estrogen A drug that binds to and breaks down proteins called estrogen receptors (ERs), which are found inside the cells of female reproductive tissue, breast tissue, Endocrine therapy resistance in ER+ metastatic breast cancer
Aditya Bardia, MD, MPH, discusses his research at the SABCS 2016 meeting. In today's top stories: - The FDA has rolled out its highly-touted generative AI tool, almost a month early, with a promise to reduce
SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer Drugs.com provides accurate and independent information on more Drug treatment for * Breast cancer * Endometrial Cancer * Prostate cancer * Alopecia * Benign prostatic hyperplasia explained Elacestrant belongs to a class of medications called selective estrogen receptor degraders (SERDs), offering a targeted approach
SERDs are medications that treat ER-positive breast cancer. There's currently only one SERD that's FDA approved for use — fulvestrant Amid staff cuts, FDA looks to AI to 'optimise' reviews #news #pharmanews #biotechnews #asco2025
ESMO: Clear air emerges between Roche SERD and its rivals #pharmanews #esmo Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer The landscape of oral SERDs and their potential in ER+ breast cancer Ask the expert: Metastatic breast cancer with Tufia C. Haddad, MD
Dr Maura Dickler, (Memorial Sloan Kettering Cancer Center, New York, USA) talks to ecancertv at AACR 2015 about a new Pharmacology-Estrogens and Antiestrogens Endocrine MADE EASY!
Preliminary data on OP-1250 + palbociclib in advanced/metastatic ER+/HER- breast cancer Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers Alana Welm, Ph.D. Senior Director of Basic Science Professor, Department of Oncological Sciences University of Utah, School of
Should you avoid estrogen in your diet during breast cancer? Does your diet make a difference if you're on an endocrine therapy? Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the monarchE and NATALEE trials, investigating CDK4/6 inhibitors
Speaker: Kevin Kalinsky, MD, MS Professor of Medicine Director, Glenn Family Breast Center Director, Breast Medical Oncology ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
Hear from Eleonora Teplinsky, MD about the most recent drug approvals in metastatic breast cancer and how they impact each Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, comments on which groups of patients will be eligible to Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and
More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent RAD1901 for Treatment of ER+ Breast Cancer
Simple and short presentation for the mechanism of action, pharmacological actions, indications and adverse effects of selective Focus On: Cancer Modeling Here's your Women's Health brief. Global experts issued unified guidance for IBD in pregnancy, supporting biologics and
Top 5 Breast/GYN Cancer Advances in 2023: #2 Metastatic Breast Cancer Drug Approvals Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, comments on the rationale and design of the ELECTRA trial
Get scanned lecture pdfs: Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Filipa Lynce, MD; and Ana C. Garrido-Castro, MD discuss
I have been randomized into the new drug arm of the CAMBRIA-2 study This review summarizes the currently available literature on this new class of drugs. Keywords: SERD; amcenestrant; breast cancer; camizestrant; elacestrant
SERDs, SERMs, CERANs, and PROTACs SERENA-2: camizestrant vs fulvestrant in post-menopausal women with advanced ER+/HER- breast cancer Dive into fulvestrant, an estrogen receptor degrader (SERD) used in hormone receptor-positive metastatic breast cancer.
Selective Estrogen Receptor Degraders (SERDs) for Metastatic Tamoxifen Raloxifene Toremifene Clomiphene. The Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2
Dr Hamilton talks to ecancer about results from VERITAC-2, the first global phase 3 clinical trial of a PROTAC, a targeted therapy Understanding Clinical Trials in Breast Cancer Treatment Breast Cancer Breakthroughs: Fitting oral SERDs into early breast cancer treatment
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, Erika Hamilton, MD, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, discusses the safety results of the Anti Cancer - Hormonal drugs [ Estrogens, SERMs, SERDs, Aromatase inhibitors etc]
Sean Bohen, MD, PhD, Olema Oncology, San Francisco, CA, shares preliminary data from a Phase Ib (NCT04505826) dose How Can I Understand Different Hormone Therapy Drugs For Breast Cancer?
Erika Hamilton, MD, and Sarah Premji, MD, of Sarah Cannon Research Institute, discuss presentations from ESMO Congress What Are The Next-generation Chemoprevention Drugs For Breast Cancer? Are you interested in the latest developments in
SERMs block estrogen receptors in the breast so that estrogen can't attach to the cancer cells and help them multiply. These medicines are selective estrogen receptor modulators (SERMs) Selective estrogen receptor degraders (SERDs) are a type of hormone therapy. These anti-estrogen drugs bind to the estrogen receptor in a tumor cell. They cause
We had the pleasure of having Melanie Sisk on the show to demystify the complex world of emerging endocrine therapies, often Richard Baird, MD, PhD, University of Cambridge, Cambridge, UK, discusses findings from Parts K and L of the Phase I
RV-471: novel PROTAC® estrogen receptor degrader, in ER+ breast cancer Oral-Based SERDs Could Bolster QOL in ER+ HER2– Breast Cancer Treatment
Tamoxifen is a medication that is commonly used in the treatment of certain types of breast cancer. It belongs to a class of drugs Genentech's Giredestrant Becomes the First Oral SERD to Show
A selective estrogen receptor degrader or downregulator (SERD) is a type of drug that selectively binds to the estrogen receptor (ER) and induces its Mafalda Oliveira, MD, PhD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, provides an overview of the Phase II How Are New Drugs Treating Metastatic Breast Cancer? In this informative video, we will discuss the latest advancements in the
SERMs and SERDs for Breast Cancer Selective estrogen receptor degrader - Wikipedia
Elacestrant: A New Weapon Against Advanced Estrogen Receptor-Positive Breast Cancer ESMO25 Breast Cancer Highlights: monarchE and NATALEE | Dana-Farber Cancer Institute Metastatic Breast Cancer Updates: SERDs, mTOR Inhibitors, and VIKTORIA-1
ESMO25 Breast Cancer Highlights Panel Discussion | Dana-Farber Cancer Institute As we countdown to #2024, let's look back at some of the top advances in breast and gynecologic cancers in 2023. *This is a list Antibody-Drug Conjugates in the Management of HR+ and Triple-Negative Metastatic Breast Cancer
What's the Best Diet for Hormone Receptor-Positive Breast Cancer? The Ultimate Guide for HR+ 15 Medicine of the week: Fulvestrant